Share on facebook Share on Twitter Share on Google Plus Share This

Cancer Center

Back to Results

Anita Kumar, MD, MS accepting new patients


Overview

Programs + Specialties
Research Interests Treatment of acute leukemia, myelodysplastic syndromes, myeloproliferative neoplasms
Health services research
Training + Education Albert Einstein College of Medicine; University of Pennsylvania Abramson Cancer Center
Board Certifications Internal Medicine, Medical Oncology
NPI # 1083876650
Gender Female

Locations + Directions

Tufts Medical Center
800 Washington St.
Box 245
Boston, MA 02111
Fax #: 617-636-8538
Phone #: 617-636-6227

Publications + National Presentations

Kumar A, Frey N, & Carver J: Inhibition of the Renin Angiotensin System During Autologous Stem Cell Transplant does not Inhibit Engraftment. Open Journal of Blood Diseases, 2: 67-70, 2012.

Kumar A, Hexner E, Frey N, Luger S, Loren A, Reshef R, Boyer J, Smith J, Stadtmauer E, Levine B, June C, Porter D, & Goldstein S: A Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation. Biology of Blood & Marrow Transplantation, 19: 1094-1101, 2013.

Kumar A, Gimotty P, Gelfand J, Buck G, Rowe J, Goldstone A, Fielding A, Marks D, Litzow M, Paietta E, Lazarus H, Tallman M, Luger S, & Loren A: Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients. Blood November 2014 (abstract, ASH 2014 Oral Presentation).

Kumar A, Frey N, Vassilev P, Goldstein S, Hexner E, Loren A, Reshef R, Luger S, Porter D, & Stadtmauer E. Time from Relapse After Allogeneic Stem Cell Transplantation to Donor Leukocyte Infusion is Longer, Incidence of GVHD is Higher, but Survival is Similar for Recipients of Unrelated DLI Compared to Matched Sibling DLI. J Clin Oncology 29: 2011 (suppl; abstract 6586).

Hsu J, Kumar A, Carroll M, Frey N, Shah N, Zhao J, Hexner E, Loren A, Mangan J, Perl A, Porter D, Morrissette J, & Luger S. ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML? Blood November 2014 (abstract, ASH 2014 Poster Presentation).

Frey NV, Perl A, Luger S, Mangan J, Hexner E, Kumar A, Porter D, Loren A, Kremer B, Luskin M, Baird J, Zebrowski A, & Carroll, M. A Phase I Study Using Single Agent Birinapant in Patients with Relapsed myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood November 2014 (abstract, ASH 2014 Poster Presentation).

Singh N, Kumar A, Gao A, Luskin M, Frey N, Hexner E, Loren A, Luger S, Stadtmauer E, Porter D, & Reshef R. Higher total nucleated cell dose is associated with improved survival in patients receiving donor lymphocyte infusion after allogeneic stem cell transplantation. JCO (abstract, ASCO 2015 Poster Presentation).

Biography

Anita Kumar, MD, MS joined the faculty of the Division of Hematology/Oncology in September 2015. Dr. Kumar will have an outpatient clinical expertise on leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. She will be attending on the oncology consult and inpatient hematologic malignancy services. Additionally, she will work on cancer survivorship efforts and health services research at Tufts with a focus on hematologic malignancies. Dr. Kumar received her MD in 2008 at the Albert Einstein College of Medicine, and then trained in Internal Medicine and completed her Hematology/Oncology fellowship at the University of Pennsylvania, where she also recently earned a Masters in Clinical Epidemiology.

Professional Memberships

American Society of Hematology (ASH)
Eastern Cooperative Oncology Group (ECOG): Leukemia ‘Core Committee’ Member